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doi:10.1016/j.jfma.2011.12.011Due to increased healthcare expenditure and the need for evidence-supported clinical deci-
sion-making, clinical evaluation using comparative effectiveness research (CER) was initially
proposed in the US. CER consists of generating and synthesizing evidence in relative benefits,
harms, and costs of different alternatives through direct head-to-head comparisons. CER
studies can help identify the most effective interventions for patients under specific circum-
stances, and therefore improve the efficiency of the healthcare system. A Biosignatures
project newly launched in Taiwan was inspired by CER, aiming at using discovered biomarkers
panel as tools in early detection of disease and prediction of treatment effectiveness.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
In the US, increasing healthcare costs have been a contro-
versial issue and the worldwide economic crisis beginning 3
years ago worsened the situation. Healthcare spending was
estimated to account for 17.6% of gross domestic product
(GDP) in 2009 and was projected to reach 20.3% of GDP by
2018.1 In addition, the Institute of Medicine (IOM)ormatics and Medical Statis-
st Road, Kwei-Shan, Taoyuan
.edu.tw (C.-J. Chang).
ight ª 2012, Elsevier Taiwan LLCestimated that less than half of medical care provided was
based on solid scientific evidence,2 which indicated the
lack of information on relative effectiveness of different
treatment options for clinical decision-making. In order to
decrease healthcare spending without compromising health
outcomes, Peter Orszag, director of the Office of Manage-
ment and Budget, proposed that: “Better information
about the costs and benefits of different treatment
options.could help reduce healthcare spending without
adversely affecting health overall.”3 He also emphasized
the importance of good evidence in reducing the growth of
healthcare spending and therefore improving the financial
sustainability of the healthcare system.4& Formosan Medical Association. All rights reserved.
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IOM suggested that a National Clinical Effectiveness
Assessment Program is needed in the US.5 Recommenda-
tions for priorities setting have become an important indi-
cation for proposed changes, i.e., the priorities of setting
up a clinical effectiveness assessment, which includes the
expectation that evidence-based practice should improve
health outcomes across a life span, reduce the burden of
disease and health disparities, and eliminate undesirable
variations. The report also recommended the consideration
of economic factors, such as the costs of treatment and the
economic burden of disease care. Due to these recom-
mendations, in the assessment of newly proposed plans of
healthcare reform, a head-to-head comparison of different
treatments, policies, and interventions should be studied
and comparative effectiveness research (CER) was thus
established in the US. Thus, effectiveness assessments not
only are studies of clinical impacts, but also take into
consideration health-related economic issues. According to
IOM’s definition, CER is “the generation and synthesis of
evidence that compares the benefits and harms of alter-
native methods to prevent, diagnose, treat, and monitor
a clinical condition or to improve the delivery of care.”6
The purpose of CER, as stated in the report to the Presi-
dent and Congress by the Federal Coordinating Council, US
Department of Health and Human Services (DHHS) on CER,
is “to inform patients, providers, and decision-makers,
responding to their expressed needs, about which inter-
ventions are most effective for which patients under
specific circumstances.”7 In 2009, the United States
Congress passed the American Recovery and Reinvestment
Act (ARRA), where US $1.1 billion was allocated to develop
and disseminate the evidence from CER.Comparative Effectiveness Research (CER) vs.
Evidence-Based Medicine (EBM)
CER is the study of comparing effects of health care
interventions for a specific condition and determining
which one achieves best health outcomes. CER shares
similarities with traditional approaches d evidence-based
medicine (EBM) d that systematically integrate individualTable 1 Summary of comparison between CER and EBM.
Characteristic CER
Comparator A head-to-head comparison of all alt
for a specific condition
Outcome Effectiveness
Study participants Study participants are representativ
patient population in clinical practi
Hierarchy of evidence/
study design
More flexible (primary CER and seco
CER)
Research topic Broader (health interventions, tests
strategies for treatments or preven
health care delivery issues)
Audience Patients, clinicians, payers, and pol
makers
CER Z comparative effectiveness research; EBM Z evidence-based mclinical expertise with the best available external clinical
evidence to provide information for clinical decision-
making.8 Both CER and EBM are aimed at finding the linkage
between health care interventions/treatments and
outcomes through statistical analyses, and providing
evidence for informed decision-making such as clinical
guidelines. In addition, both can promote patient-centered
decision-making because evidence from CER and EBM can
help identify which medical strategy works for patients
with specific characteristics.
Some characteristics of CER, however, distinguish it
from EBM.6,9 Comparisons between CER and EBM are
summarized in Table 1. CER emphasizes direct head-to-
head comparisons of different alternatives targeting
health conditions or healthcare delivery issues. On the
contrary, EBM aims to examine if a treatment works by
usually comparing it with no treatment. However, to make
an informed decision it is necessary to compare different
strategies simultaneously, either by synthesizing existing
evidence, or by generating new evidence through con-
ducting appropriate studies.
One of the major disparities between CER and EBM is
that while EBM examines efficacy of a medical intervention,
CER aims to compare effectiveness of different health
interventions. As a result, study populations for CER should
be representative of patient populations of interest in real-
world clinical practice, whereas study participants for EBM
are carefully selected according to predefined inclusion
criteria and are fairly homogeneous. The gold standard of
EBM is randomized clinical trials (RCTs) that have high
internal validity but low external validity. CER has greater
methodological flexibility to improve external validity. The
methodological approaches of CER consist of synthesizing
evidence from existing studies through systematic review
and decision modeling (primary CER), and conducting
research, including experimental, retrospective, prospec-
tive, and observational studies (secondary CER). The
emphasis on effectiveness and application of different
research methods and data for a broad range of CER topics
such as health interventions, tests and strategies for
treatments or prevention, health care delivery issues, or
reimbursement and coverage decisions, distinguishes CER
from EBM, which focuses on narrower clinical questionsEBM
ernatives A head-to-head comparison of a treatment
and placebo for a specific condition
Efficacy
e of
ce
Study participants are carefully selected
based on predefined inclusion criteria
ndary Randomized clinical trials at the top of the
hierarchy
, and
tion, or
Clinical questions (e.g. health interventions,
risk factors, diagnosis, and prognosis)
icy Physicians and patients
edicine.
Table 2 List of 100 recommended research priorities by
research area.6
Category Number
of topics
Health care delivery systems 23
Cardiovascular and peripheral vascular disease 8
Psychiatric disorders 7
Neurologic disorders 6
Oncology and hematology 6
Musculoskeletal disorders 5
Women’s health 5
Racial and ethnic disparities 3
Infectious diseases 3
Skin disorders 3
Birth and developmental disorders 3
Nutrition (including obesity) 3
Complementary and alternative medicine 3
Geriatrics 2
Functional limitations and disabilities 2
Endocrinology and metabolism disorders 2
Alcoholism, drug dependency, and overdose 2
Eyes, ears, nose, and throat disorders 2
Kidney and urinary tract disorders 2
Oral health 2
Palliative and end-of-life care 2
Pediatrics 1
Immune system, connective tissue,
and joint disorders
1
302 J.-S. Cheng et al.such as health interventions, risk factors, diagnosis, and
prognosis. The audience of CER is also broader than that of
EBM. CER aims to answer questions relevant to a broad
range of beneficiaries, including patients, clinicians,
payers, and policy makers. EBM aims to help physicians and
patients make clinical decisions.
However, there are some weaknesses of CER studies.
Most research designs in clinical studies focus on carrying
out complicated study practices such as clinical trials
because, in traditional hierarchies of evidence, these
command the highest level of evidence. In the concept of
CER, both experimental and non-experimental methods
can be adopted to evaluate treatment effectiveness in
a heterogeneous disease population in real-world practice
settings to provide reliable and timely information for
decision-making. However, the extent to which CER can
be applied to patient-level and policy-level decision-
making depends on how well it can provide relevant,
reliable, and timely evidence. Tunis et al suggested that in
addition to the participation of patients, consumers,
clinicians, payers, and policy makers in the design and
implementation of CER studies, the improvement of the
research methods and infrastructure for CER requires
substantial attention.10 Improving these existing
approaches and developing analytic methods are of
importance to improve the quality of CER studies by, for
example, the adoption of pragmatic clinical trials and the
development and adoption of adequate analytic methods
for observational studies.5,11,12Trauma, emergency medicine,
and critical care medicine
1
Respiratory disease 1
Gastrointestinal system disorders 1
Liver and biliary tract disorders 1
Total 100Biosignatures with CER in Taiwan
When it comes to decision-making about the use of or reim-
bursement for health technologies (medications, medical
devices, etc.), Health Technology Assessment (HTA), which
uses cost-effectiveness analysis (CEA) or cost-utility analysis
(CUA), has been widely adopted around the world, including
Taiwan.13e15 The Bureau of National Health Insurance (BNHI)
of Taiwan’s Department of Health has been aware of the
need to obtain information for decision-making regarding
relative effectiveness and costs, if available, of health
technologies of interest andalternative treatment strategies
for patients with a specific health condition. Therefore, in
addition to the establishment of the HTA task force, an HTA
policy was introduced for pharmaceutical manufacturers
applying for approval of enlisting drugs in the NHI formulary,
which encourages rather than mandates the submission of
cost-effectiveness evaluation that reflects real-world clin-
ical practices in Taiwan.
However, the CER concept points out that there is
a need to compare comprehensive interventions for health
conditions of interest and to take into account a wide range
of health-related outcomes for different patient pop-
ulations in real-world practice. In the US, a survey of
professional organizations and the public was performed by
the IOM and initial national priorities for CER were sug-
gested, which include 100 health/medical/disease related
conditions (Table 2).4,6,16 Although healthcare delivery
systems are among the top priorities for CER, certain
disease management scenarios such as cardiovascular and
peripheral vascular disabilities, neurologic disorders, andpsychiatric disorders were among the top quarter. If such
priorities can be established at a national level in Taiwan
through government surveys and proper CER studies can be
conducted, the best interventions for patients with certain
characteristics can be identified. If costs have been taken
into account in the CER studies, more cost-effective
treatment strategies can be identified and substituted for
less cost-effective ones. As a result, even if overall
healthcare spending is not reduced, the efficiency of the
healthcare system, or the incremental gain in health per
dollar spent, can be increased.17
In recent years, as genetic and molecular markers have
been quickly discovered to be associated with treatment
responses and disease development, more and more
personalized medicine such as genomic tests have been
adopted to determine treatment choices. For example, in
Taiwan, testing for human epidermal growth factor
receptor type 2 (HER2) and the KRAS mutation has been
adopted to determine who is more likely to be responsive to
trastuzumab and cetuximab, respectively.18,19 Testing for
HLA-B1502 is used to predict who is more likely to
suffer from StevenJohnson Syndrome/Toxic Epidermal
Necrolysis (SJS/TEN) by taking carbamazepine.20 However,
a lack of properly designed studies to evaluate the clinical
Biosignatures: CER in biomarker clinical studies 303utility of personalized medicine is the greatest barrier to
adoption in clinical practices. Therefore, with adequate
methodological approaches from CER, it can be assessed
whether adoption of personalized medicine such as
genomic testing can increase patient outcomes.21,22
Biomarker discovery certainly plays an important role
in disease management, ranging from early detection in
a high-risk group to homogeneous subgroup selection in
treatment with personalized medicine. The validation of
the useful biomarkers requires huge efforts and monetary
resources, not only in laboratory technology but also in the
conduct of clinical studies. From taking the patients’
perspective, to the validation of biomarkers assisting in
treatment of diseases such as cancer, a head-to-head
comparison using CER approaches before conducting clin-
ical studies will provide information on relative effective-
ness in many scenarios and in a broader viewpoint.Table 3 Examples of biomarker studies in Taiwan.
Disease Biomarker Exam
Hepatocellular cancer
(HCC)
1. The serum/ plasma
markers of HBV or HCV
infection
HBsA
core
anti
2. Biomarkers of exposure Afla
arom
met
prot
3. Biologic response
markers
Spec
p53
Non-small cell lung
carcinoma
(NSCLC) in woman
Gene expression SEM
Lung cancer Gene or microRNA
expression
The
cont
or m
Gastric cancer MicroRNA expression miR
expr
Neuroblastoma MicroRNA expression 12 m
References:
1 Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY,
infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol
2 Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL
subsequent risk of hepatocellular carcinoma: Long-term predic
2010;28:458793.
3 Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, Chen CJ.
chronic hepatitis B virus infection. J Clin Oncol 2010;28:243744.
4 Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, Tsai WY, Sa
aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Re
5 Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, Shih JY, Yang PC,
SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Ca
6 Chen HY, Yu SE, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL
Chen WJ, Chen JJ, Yang PC. A five-gene signature and clini
2007;356:11e20.
7 Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL,
Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC
Cancer Cell 2008;13:48e57.
8 Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH, Kao HW, Fang WL, H
miR-129 expression in gastric cancer. Int J Cancer 2011 (in press).
9 Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni MB, London W, C
Drosha can predict prognosis and delineate risk groups in neuroblastoThe concept of applying CER to clinical studies has
drawn lots of attention from the clinical research society in
Taiwan in recent months. A Biosignatures Initiative work-
shop hosted by Academia Sinica and initiated by Nobel Prize
Laureate Prof. Lee Hartwell and Prof. Scott Ramsey, pres-
ident of International Society for Pharmacoeconomics and
Outcomes Research, took place in early January 2011. To
improve the outcomes of disease treatment in human
beings, and to reduce the medical and societal costs of
disease treatments are the main goals of the Biosignatures
Initiative. It was estimated that discovery of new
biomarkers increased 10 fold since 1990. But how do these
newly discovered biomarkers effectively help in identifying
risks in early stage of disease? Providing effective treat-
ments and early detection for high-risk groups becomes
challenging work. Collaboration among different research
teams is necessary so as to reach an agreement to theple Clinical use Reference
g, HBeAg, anti-HBV
antigen, anti-HBV e
gen, and anti-HBsAg
Monitoring 1,2,3
toxin and polycyclic
atic hydrocarbon
abolites, and DNA and
ein adducts
Monitoring 1
ific mutations in the
gene
Monitoring 4
A5A Prognosis 5
sum of weighted
ribution of each gene
icroRNA
Diagnosis/ prognosis 6,7
-34b and miR-129
ession
Prognosis 8
iRNAs’ signature Prognosis 9
Chen CJ, Santella RM. Aflatoxin B1 exposure, hepatitis B virus
Biomarkers Prev 2009;18:84653.
, Wang LY, Chen WJ, Chen CJ. Hepatitis C virus seromarkers and
tors from a community-based cohort study. J Clin Oncol
Nomograms for risk of hepatocellular carcinoma in patients with
ntella RM. p53 mutations, chronic hepatitis B virus infection, and
s 1997;57:34717.
Hsiao CK, Lai LC, Chuang EY. Identification of a novel biomarker,
ncer Epidemiol Biomarkers Prev 2010;19:25907.
, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S,
cal outcome in non-small-cell lung cancer. N Engl J Med
Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY,
. MicroRNA signature predicts survival and relapse in lung cancer.
uang KH, Chan WC, Lin WC. Epigenetic regulation of miR-34b and
hang JCH, Yu AL. MicroRNA signature and expression of Dicer and
ma. Cancer Res 2010;70:78417850.
304 J.-S. Cheng et al.treatment management of these severe diseases. The Bio-
signatures Institute is a collaborative organization among
different specialties; it involves the expertise from clini-
cians, basic scientists, bio and medical informatics,
biostatistician and health/pharmaco-economists. Diseases
selected for CER exploration studies in the Biosignatures
project must follow certain criteria. The criteria require
that there are enough clinical expertise and a large patient
volume with an identifiable at-risk population in Taiwan;
whether the disease has local relevance and rapid
progression that will allow for immediate intervention;
whether there are opportunities to improve the outcomes
and change the clinical care pathway; whether the
biomarkers panel is ready to utilize and conduct the clinical
trials to possibly improve the clinical outcomes; and
whether the clinical information, such as a national level
database, are accessible for economic evaluation. An early
detection of oral squamous cell carcinoma (OSCC) CER
study has been selected as a Biosignatures project using the
criteria in Chang Gung University and Chang Gung Memorial
Hospital. The study is aimed at validating useful biomarker
panels to establish a head-to-head comparison for further
cost-effectiveness analysis, and to eventually improve
OSCC outcome and simultaneously reduce treatment cost.
Currently, there are other research teams studying
biomarkers of different cancers such as hepatocellular
cancer, non-small cell lung cancer, lung cancer, and gastric
cancer for different clinical purposes in Taiwan (Table 3).
CER can also be adopted to evaluate cost-effectiveness of
adopting these biomarker tests in clinical practice.
Conclusion
In order to improve health outcomes, it is important to
identify the most effective interventions such as biomarkers
for specific patient populations. Provided that there is
limited evidence, which systematically compares all rele-
vant interventions to examine the best ones for patientswith
specific characteristics, CER can be conducted to help make
informed and evidence-supported patient-centered deci-
sions. By conducting cost-effective analysis, the most cost-
effective medical intervention can be adopted to increase
the efficiency of the healthcare system.However, the extent
to which CER studies can be applied to change medical
practices depends on how well the studies can provide
relevant, reliable, and timely evidence that are useful for
decision-making.
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